ImmunityBio (IBRX) is trading higher after disclosing preliminary Q1 2026 net product revenue of approximately $44.2 million, representing ~168% growth versus Q1 2025 and about a 15% sequential increase from Q4 2025. The company attributed the momentum to continued U.S. adoption of ANKTIVA by urologists and emphasized an improved liquidity position with $381 million in cash and marketable securities as of March 31, 2026. (immunitybio.com)

For a commercial-stage biotech, the market tends to re-rate the equity when product revenue shows repeatable quarterly progression rather than one-time stocking or launch volatility. ImmunityBio framed the quarter as another step in consistent post-launch growth, which can reduce financing anxiety and shift investor focus toward label expansion and international rollout as upside drivers. (immunitybio.com)

The revenue strength lands amid heightened attention on regulatory execution and communications. In early April 2026, ImmunityBio filed an 8-K describing its response and corrective actions tied to the FDA’s March 13, 2026 warning letter regarding promotional materials for ANKTIVA, a topic that has also contributed to lawsuit-related volatility in recent weeks. (sec.gov)

Traders will likely focus on whether preliminary revenue translates into a strong finalized quarterly filing and whether demand can stay durable as the company pursues additional label opportunities. Near-term catalysts include future regulatory milestones for supplemental filings and any updates that clarify the operational impact of the FDA promotional compliance process. (immunitybio.com)